Last reviewed · How we verify
NaCl 9% isotonic
NaCl 9% isotonic solution restores and maintains electrolyte balance and fluid volume in the body.
NaCl 9% isotonic solution restores and maintains electrolyte balance and fluid volume in the body. Used for Hypovolemia and shock management, Severe hyponatremia correction, Fluid resuscitation in critical care settings.
At a glance
| Generic name | NaCl 9% isotonic |
|---|---|
| Also known as | fluid replacement |
| Sponsor | Centre Hospitalier Universitaire de Nice |
| Drug class | Electrolyte replacement solution |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Fluid and Electrolyte Management |
| Phase | FDA-approved |
Mechanism of action
This is a hypertonic saline solution containing 9% sodium chloride, used to restore intravascular volume and correct severe hyponatremia or hypervolemia. It works by osmotic action, drawing fluid into the intravascular space and correcting electrolyte imbalances. It is a basic physiological replacement therapy rather than a drug with a specific molecular target.
Approved indications
- Hypovolemia and shock management
- Severe hyponatremia correction
- Fluid resuscitation in critical care settings
Common side effects
- Hypernatremia (if over-administered)
- Phlebitis at infusion site
- Hyperchloremic acidosis
- Fluid overload
Key clinical trials
- Volume Reduction for Open Fracture Irrigation (PHASE4)
- Corticosteroids to Treat Pancreatitis (PHASE2)
- The Intravenous Amino Acid Therapy for Vascular Rigidity in End Stage Renal Disease (NA)
- Sublingual Atropine Bioequivalence by Route of Administration (SABER) (PHASE1)
- Healing Efficacy of Isobutyl Cyanoacrylate High Viscous Solution in Treatment of Traumatic Ulcer in Children (NA)
- Bronchiolitis Clearance Airways With Seaserum (NA)
- DMID 23-0015; Lassa Fever CVD 1000 (PHASE1)
- Treatment of Orthostatic Intolerance (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NaCl 9% isotonic CI brief — competitive landscape report
- NaCl 9% isotonic updates RSS · CI watch RSS
- Centre Hospitalier Universitaire de Nice portfolio CI